Amgen (NQ:AMGN)

414.87 +7.43 (+1.82%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Amgen

< Previous 1 2 3 4 5 Next >

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

May 13, 2026

Via Investor Brand Network

InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery

May 13, 2026

Via Investor Brand Network

Topics Intellectual Property

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly

May 11, 2026

Via Investor Brand Network

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

May 13, 2026

From BioMedWire

Via GlobeNewswire

The Next Generation of the GLP-1 Revolution Is Already Underway

May 11, 2026

Via Investor Brand Network

The Next Generation of the GLP-1 Revolution Is Already Underway

May 11, 2026

From BioMedWire

Via GlobeNewswire

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

December 04, 2025

Via Investor Brand Network

Topics Government

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

December 04, 2025

From BioMedWire

Via GlobeNewswire

Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

September 09, 2025

From Kyowa Kirin

Via GlobeNewswire

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

August 06, 2025

Via Investor Brand Network

Topics Government

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

August 06, 2025

EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

March 05, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 15, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Eli Lilly’s Path to the Next Trillion Market Capitalization

August 26, 2024

Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.

Via MarketBeat

MarketBeat Week in Review – 8/5 - 8/9

August 10, 2024

Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings

Via MarketBeat

Topics Economy

Amgen's MariTide Weight Loss Potential: Stock Outlook

August 07, 2024

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.

Via MarketBeat

Topics Intellectual Property

CPI Data Sparks Rally in Biotech Stocks

July 15, 2024

Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.

Via MarketBeat

Topics ETFs Economy

Positive News is Driving This Cancer Drug Maker’s Stock Higher

July 15, 2024

IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather

Via MarketBeat

Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex

July 02, 2024

The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.

Via MarketBeat

Topics ETFs

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

June 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines

June 17, 2024

Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA

Via MarketBeat

Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

June 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Biotech Sector Nears Breakout: Will it Outperform in Q2?

April 03, 2024

The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains

Via MarketBeat

Topics ETFs

7 Stocks That Will Drive the Weight Loss Drugs Market

March 28, 2024

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

Via MarketBeat

4 Oversold Large Cap Stocks Yielding High Dividends

March 14, 2024

Overlooked, oversold large-cap stocks offer compelling dividend yields for investors seeking income and potential capital appreciation

Via MarketBeat

Topics Artificial Intelligence Economy

Amazon Stock: Why it's Finally Included in the Dow Index

February 29, 2024

Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting.

Via MarketBeat

Topics Economy Stocks

Are these frigid Dow stocks in for a longer winter?

February 08, 2024

These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages.

Via MarketBeat

Topics Economy Stocks

IBM, Verizon, Merck stocks lead Dow to new highs

January 31, 2024

The Dow hits record highs with IBM, Verizon, Merck, and insurer Travelers leading the way; those strong stocks don't make much of a dent in S&P performance

Via MarketBeat

Topics Stocks

5 top healthcare stocks for earnings growth in 2024

January 25, 2024

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

Via MarketBeat

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.